• Home
  • NEW DAY MEDICINE
  • 2 (64) 2024
  • 48 -2 (64) 2024 - Muminov B.A., Matmurodov R.J., Xalimova X.M. - CLINICAL CHARACTERISTICS OF PATIENTS WITH PARKINSON’S DISEASE AFTER COVID-19

48 -2 (64) 2024 - Muminov B.A., Matmurodov R.J., Xalimova X.M. - CLINICAL CHARACTERISTICS OF PATIENTS WITH PARKINSON’S DISEASE AFTER COVID-19

CLINICAL CHARACTERISTICS OF PATIENTS WITH PARKINSON’S DISEASE AFTER COVID-19

Muminov B.A. Tashkent Medical Academy

Matmurodov R.J. Tashkent Medical Academy

Xalimova X.M. Tashkent Medical Academy

Resume

The features of early diagnosis and treatment of diabetic polyneuropathy in adults, which is one of the most important medical and social problems, are considered. Was assessed of intensity of the pain syndrome.

Keywords: Covid-19, Parkinson's disease, characteristics

First page

310

Last page

315

For citation: Muminov B.A., Matmurodov R.J., Xalimova X.M. - CLINICAL CHARACTERISTICS OF PATIENTS WITH PARKINSON’S DISEASE AFTER COVID-19//New Day in Medicine 2(64)2024 310-315 https://newdayworldmedicine.com/en/article/3758

List of References

  1. Иллориошкин С.Н. Болезнь Паркинсона в эпоху пандемии Covid-19 // Нервные болезни. 2021;4:11-18.
  2. Matmurodov R.J., Umirova S.M., Koronavirus infeksiyasining diabetik polineyropatiyalar rivojlanishidagi roli va uning komplement tizimiga ta’siri // Biomeditsina va amaliyot jurnali, Tadqiqot.uz., Toshkent-2021;6(3):256-263.
  3. Matmurodov R.J., Umirova S.M., Covid-19 o‘tkazgan diabetik polineyropatiyali bemorlarda klinik-nevrologik, neyrofiziologik buzilishlar va komplement S3 komponentining solishtirma tahlili // Journal of neurology and neurosurgery research. Toshkent 2023;3:51-55.
  4. Xalimova X.M., Matmurodov R.J., Umirova S.M., Covid-19 o‘tkazgan bemorlarda diabetik polineyropatiyalarning dinamikasini baholash // Biomeditsina va amaliyot jurnali, Tadqiqot.uz., Toshkent 2023;8(3):310-314.
  5. Alipoor SD, Mortaz E, Varahram M, Garssen J, Adcock IM. The immunopathogenesis of neuroinvasive lesions of SARS-CoV-2 infection in COVID-19 patients. // Frontiers in Neurology 2021 Jul;12:6970-79.
  6. Artusi CA, Romagnolo A, Ledda C, Zibetti M, Rizzone MG, Montanaro E, Bozzali M, Lopiano L. COVID-19 and Parkinson’s disease: what do we know so far? // Journal of Parkinson’s Disease 2021;11(2):445-54.
  7. Baschi R et al. Changes in motor, cognitive, and behavioral symptoms in Parkinson’s disease and mild cognitive impairment during the COVID-19 lockdown. // Front. Psychiatry. 2020;11:590134.
  8. Beauchamp LC, Finkelstein DI, Bush AI, Evans AH, Barnham KJ. Parkinsonism as a third wave of the COVID-19 pandemic? // Journal of Parkinson’s Disease 2020;10(4):1343-53.
  9. Boesl F, Audebert H, Endres M, Prüss H, Franke C. A neurological outpatient clinic for patients with post-COVID-19 syndrome – a report on the clinical presentations of the first 100 patients. // Frontiers in Neurology 2021 Sep;12:738405.
  10. Brundin P, Nath A, Beckman JD. Is COVID-19 a perfect storm for Parkinson’s disease? // Trends in Neurosciences 2020 Dec;43(12):931-3.
  11. Cohen ME, Eichel R, Steiner-Birmanns B, Janah A, Ioshpa M, Bar-Shalom R, Paul JJ, Gaber H, Skrahina V, Bornstein NM, Yahalom G. A case of probable Parkinson’s disease after SARS-CoV-2 infection. // The Lancet. Neurology 2020 Oct;19(10):804-5.
  12. Chaudhry ZL, Klenja D, Janjua N, Cami-Kobeci G, Ahmed BY. COVID-19 and Parkinson’s disease: shared inflammatory pathways under oxidative stress. // Brain Sciences 2020 Oct;10(11):807.
  13. D. Sulzer, A. Antonini, V. Leta, A. Nordvig, R.J. Smeyne, J.E. Goldman, O. Al-Dalahmah, L. Zecca, A. Sette, L. Bubacco, O. Meucci, E. Moro, A.S. Harms, Y. Xu, S. Fahn, K. Ray Chaudhur COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside NPJ Parkinsons Dis. (2020):6-10.1038/s41531-020-00123-0
  14. Faber I, Brandão PRP, Menegatti F, de Carvalho Bispo DD, Maluf FB, Cardoso F. Coronavirus disease 2019 and Parkinsonism: a non-post-encephalitic case. Movement Disorders 2020 Oct;35(10):1721-2.
  15. Fanciulli A., Habek M., Carneiro D. et al. COVID-19: statement by the Autonomic nervous system disorders Scientific Panel. April
  16. 2020. Available at: https://www.eanpages.org/2020/04/17/covid-19-statement-by-the-autonomic-nervous-system-disorders-scientific-panel.
  17. Fearon C, Fasano А. Parkinson’s disease and the COVID-19 pandemic. // Journal of Parkinson’s Disease 2021;11(2):431-44.
  18. Giyosova N.O. Functional State of the Kidneys in Patients with Arterial Hypertension with Chronic Heart Failure Functional Class II–III in the PostCovid Period // American Journal of Medicine and Medical Sciences 2023;13(8):28(14.0.0.00)
  19. Khalimova Kh.M., Matmurodov R.J., Umirova S.M., Clinical course characteristics of diabetic polyneuropathies in patients with coronavirus // Journal of pharmaceutical negative results, vol. 13 special issue 07 (2022) Pub.:2022;12(6):2420-2426.
  20. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. // Multiple Sclerosis and Related Disorders 2020 Jul;42:102-163.

    file

    download